Finding a Better Way: Genomic Distinctiveness Kyle B. Brothers - - PowerPoint PPT Presentation

finding a better way
SMART_READER_LITE
LIVE PREVIEW

Finding a Better Way: Genomic Distinctiveness Kyle B. Brothers - - PowerPoint PPT Presentation

Finding a Better Way: Genomic Distinctiveness Kyle B. Brothers Genomics and Ethics in Research and Medical Decision-Making Cincinnati, OH March 13, 2015 Debates over genomic exceptionalism Overview Clinical analogies Genomic


slide-1
SLIDE 1

Finding a Better Way:

Genomic Distinctiveness

Kyle B. Brothers

Genomics and Ethics in Research and Medical Decision-Making Cincinnati, OH March 13, 2015

slide-2
SLIDE 2

Overview

  • Debates over genomic

exceptionalism

  • Clinical analogies
  • Genomic Distinctiveness
slide-3
SLIDE 3

Genomic Exceptionalism

slide-4
SLIDE 4

Definitions

  • -ome = noun suffix indicating “all of the specified

constituents of a cell, considered collectively or in total”

  • -omic = adjective suffix with same meaning
slide-5
SLIDE 5

Genomic Exceptionalism

  • Large number of findings generated

simultaneously

  • High likelihood of secondary finding
slide-6
SLIDE 6

Genomic Exceptionalism

Results may need filtering due to:

  • Genomics
  • Overwhelming number of secondary findings
  • Genetics
  • “Right not to know”
  • “Right to an open future”
slide-7
SLIDE 7

Debate Over ACMG Recommendations

slide-8
SLIDE 8

ACMG Recommendations

“[W]e felt that clinicians and laboratory personnel have a fiduciary duty to prevent harm by warning patients and their families about certain incidental findings and that this principle supersedes concerns about autonomy, just as it does in the reporting of incidental findings elsewhere in medical practice.”

slide-9
SLIDE 9

Critique of Recommendations

“Rejecting the need for the patient’s informed consent to look for mutations in a predetermined list of 57 genes is a profound departure from prevailing law and norms.”

slide-10
SLIDE 10

Response to Critique

“To date, the traditions of genetic testing and reporting have exceptionalized all genetic risk information as potentially dangerous to the well- being of patients. This tradition, in the era of genome sequencing, must be reconsidered.”

slide-11
SLIDE 11

Clinical Analogies

slide-12
SLIDE 12

Imaging

slide-13
SLIDE 13

Imaging

  • CT and MRI capture

“whole” part of the body

  • High likelihood of incidental

findings

  • Confirmation potentially

risky Genomics

  • WGS captures “whole”

genome

  • High likelihood of secondary

findings

  • Confirmation potentially

risky

slide-14
SLIDE 14

Imaging

  • Images display incidental

findings by default

  • Filtering requires

sophisticated image processing

  • “Incidental”

Genomics

  • Secondary findings are

hidden by default

  • Filtering can be achieved by

narrowing analysis

  • “Secondary”
slide-15
SLIDE 15

Imaging

  • Incidental findings

infrequent

  • Narrow scope of possible

findings Genomics

  • Almost every patient has

secondary findings

  • Potential for secondary

findings related to every

  • rgan system
slide-16
SLIDE 16

Imaging vs. Genomics

  • Similar in some ways, different in others
  • These differences could justify differences in

practice

slide-17
SLIDE 17

Newborn Screening

slide-18
SLIDE 18

NBS

  • New technology (tandem

mass spec) provides cheap, easy alternative to multiple existing technologies

  • Also generates large

number of results that were not previously obtained Genomics

  • New technology (WGS)

provides cheap, easy alternative to multiple existing technologies

  • Also generates large

number of results that were not previously obtained

slide-19
SLIDE 19

NBS

  • Many secondary findings

reflect circumstances that are ambiguous – not clear- cut pathology

  • Confirmatory testing can

take time, cause stress Genomics

  • Many secondary findings

reflect circumstances that are ambiguous – not clear- cut pathology

  • Confirmatory testing can

take time, cause stress

slide-20
SLIDE 20

NBS

  • Results:
  • Reflect current metabolic

state

  • Are proximal to clinical

signs and symptoms

  • Reflect potential current

disease state Genomics

  • Results:
  • Reflect genetic

composition

  • Are distal from clinical

signs and symptoms

  • Typically reflect disease

risk

slide-21
SLIDE 21

NBS

  • Typically performed:
  • In public health setting
  • On healthy patients
  • In infants

Genomics

  • Typically performed:
  • In research or clinical

setting

  • On patients with clinical

indication

  • In adults or children
slide-22
SLIDE 22

NBS vs. Genomics

  • Similar in some ways, different in others
  • These differences could justify differences in

practice

slide-23
SLIDE 23

Routine Laboratory Panels

slide-24
SLIDE 24

Typical Laboratory Panels

  • Complete Blood Count:
  • Parameters for variety of cells in the blood
  • Basic Metabolic Panel:
  • 7-8 parameters reflecting fluid and electrolyte status
  • Complete Metabolic Panel:
  • BMP + liver and nutritional parameters
slide-25
SLIDE 25

Routine Lab Panels

  • Laboratory devices generate

“package” of findings

  • Not practical to account for

individual preferences in components of package

  • Generates unexpected findings

that may need to be addressed

Genomics

  • Secondary findings could be

considered “part of the package”

  • Concerns about practicality of

accounting for preferences

  • Can generate unexpected

findings that may need to be addressed

slide-26
SLIDE 26

Routine Lab Panels

  • Limitations and implications

well understood

  • “Package” is routinely filtered,

since laboratory devices can generate more parameters than requested

Genomics

  • Limitations and implications still

poorly understood

  • Concern that failure to analyze

for important incidental findings would be unethical

slide-27
SLIDE 27

Imaging vs. Genomics

  • Similar in some ways, different in others
  • These differences could justify differences in

practice

slide-28
SLIDE 28

Antibiotic Sensitivities

slide-29
SLIDE 29
slide-30
SLIDE 30

Antibiotic Sensitivity Reports

  • Potential to generate large

number of findings

  • Total number determined by

analytical decisions

Genomics

  • Potential to generate large

number of findings

  • Total number determined by

analytical decisions

slide-31
SLIDE 31

Antibiotic Sensitivity Reports

  • Filtering is common practice;

sensitivities to expensive or restricted antibiotics are suppressed to influence provider practice

Genomics

  • Concerns about filtering

include:

  • Liability for not reporting

potentially useful information

  • Paternalistic laboratory

practices

slide-32
SLIDE 32

Antibiotic Sensitivities vs. Genomics

  • Similar in some ways, different in others
  • These differences could justify differences in

practice

slide-33
SLIDE 33

Genomic Distinctiveness

slide-34
SLIDE 34

Genomics is different, should be treated differently. Genomics is the same, should be treated the same.

Dualist Perspectives

slide-35
SLIDE 35

Exceptionalism in Practice

  • In many debates, both sides accuse the other of

exceptionalism

  • Most deny accusations of exceptionalism
  • Not useful for clarifying the issues
slide-36
SLIDE 36

Distinctiveness

  • Every domains of medicine reflects distinctive

traits

  • Each trait is shared with other domains
  • Unique combination of traits defines each domain
slide-37
SLIDE 37

Genomic Distinctiveness

Identify Partial Analogy Claim Practice Should Be The Same

slide-38
SLIDE 38

Genomic Distinctiveness

Identify Relevant Traits Determine Implications

  • f Traits

Decide on Practices

slide-39
SLIDE 39

Thanks!

  • Aaron Goldenberg
  • Nanibaa’ Garrison
  • Rich Sharp
  • Jen McCormick